A newly updated nucleic acid amplification technique promises faster and more comprehensive detection of Mycoplasma contamination in biologic drugs. The method described by Genetic Engineering News provides both broad species coverage and high sensitivity, addressing a critical quality control need in bioprocessing.
The tool is designed to detect a wide range of Mycoplasma species, a common contaminant in cell culture-based production. Its enhanced sensitivity allows for earlier identification of contamination, which can compromise product safety and yield in biologics manufacturing.
This development targets both in-process control and final product release testing, where rapid and reliable results are essential. Traditional culture-based methods can take weeks, while this amplification approach delivers results in hours, enabling quicker decision-making and reduced risk of batch loss.
The technique's applicability across different biologics—including monoclonal antibodies and vaccines—positions it as a versatile asset for manufacturers. However, specific performance data, such as detection limits or comparison to gold-standard methods, were not detailed in the announcement.
While the method shows promise, experts caution that validation against existing regulatory standards—such as those from the FDA or EMA—remains necessary before widespread adoption. The absence of peer-reviewed clinical data in this report limits assessment of its real-world reliability.